These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25178713)

  • 21. Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
    Masri S; Phung S; Wang X; Chen S
    J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):277-82. PubMed ID: 19897035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy.
    Creevey L; Bleach R; Madden SF; Toomey S; Bane FT; Varešlija D; Hill AD; Young LS; McIlroy M
    Mol Cancer Ther; 2019 Oct; 18(10):1731-1743. PubMed ID: 31289138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer.
    Tokunaga E; Hisamatsu Y; Taketani K; Yamashita N; Akiyoshi S; Okada S; Tanaka K; Saeki H; Oki E; Aishima S; Oda Y; Morita M; Maehara Y
    Cancer Med; 2013 Dec; 2(6):763-73. PubMed ID: 24403250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.
    López-Knowles E; Wilkerson PM; Ribas R; Anderson H; Mackay A; Ghazoui Z; Rani A; Osin P; Nerurkar A; Renshaw L; Larionov A; Miller WR; Dixon JM; Reis-Filho JS; Dunbier AK; Martin LA; Dowsett M
    Breast Cancer Res; 2015 Mar; 17(1):35. PubMed ID: 25888249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.
    Lui A; New J; Ogony J; Thomas S; Lewis-Wambi J
    BMC Cancer; 2016 Jul; 16():487. PubMed ID: 27421652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.
    Anderson H; Hills M; Zabaglo L; A'hern R; Leary AF; Haynes BP; Smith IE; Dowsett M
    Ann Oncol; 2011 Aug; 22(8):1770-6. PubMed ID: 21285137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer.
    Lu Q; Xia W; Lee K; Zhang J; Yuan H; Yuan Z; Shi Y; Wang S; Xu F
    Oncologist; 2020 Jan; 25(1):21-e15. PubMed ID: 31434793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER
    Amaral C; Correia-da-Silva G; Almeida CF; Valente MJ; Varela C; Tavares-da-Silva E; Vinggaard AM; Teixeira N; Roleira FMF
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
    Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
    J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
    Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
    Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.
    Ghazoui Z; Buffa FM; Dunbier AK; Anderson H; Dexter T; Detre S; Salter J; Smith IE; Harris AL; Dowsett M
    Clin Cancer Res; 2011 May; 17(9):3005-12. PubMed ID: 21325071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors.
    Varešlija D; McBryan J; Fagan A; Redmond AM; Hao Y; Sims AH; Turnbull A; Dixon JM; Ó Gaora P; Hudson L; Purcell S; Hill AD; Young LS
    Clin Cancer Res; 2016 Jun; 22(11):2765-77. PubMed ID: 26763249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
    Rechoum Y; Rovito D; Iacopetta D; Barone I; Andò S; Weigel NL; O'Malley BW; Brown PH; Fuqua SA
    Breast Cancer Res Treat; 2014 Oct; 147(3):473-85. PubMed ID: 25178514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.
    Chan HJ; Petrossian K; Chen S
    J Steroid Biochem Mol Biol; 2016 Jul; 161():73-83. PubMed ID: 26277097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors.
    Augusto TV; Amaral C; Varela CL; Bernardo F; da Silva ET; Roleira FFM; Costa S; Teixeira N; Correia-da-Silva G
    J Steroid Biochem Mol Biol; 2019 Dec; 195():105486. PubMed ID: 31557516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Wang L; Chan MS; Wing L; Yiu CC; Chow LW; Sasano H
    Horm Cancer; 2011 Feb; 2(1):73-81. PubMed ID: 21761341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy.
    Bleach R; Madden SF; Hawley J; Charmsaz S; Selli C; Sheehan KM; Young LS; Sims AH; Souček P; Hill AD; McIlroy M
    Clin Cancer Res; 2021 Jul; 27(14):3980-3989. PubMed ID: 34016642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
    Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
    PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Yiu CC; Chanplakorn N; Chan MS; Loo WT; Chow LW; Toi M; Sasano H
    Anticancer Res; 2010 Sep; 30(9):3465-72. PubMed ID: 20944124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor microenvironmental growth factors induce long-term estrogen deprivation resistance in breast cancer.
    Tsuboi K; Uematsu C; Yamaguchi Y; Niwa T; Hayashi SI
    Breast Cancer; 2019 Nov; 26(6):748-757. PubMed ID: 31119683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.